Tumor-induced osteomalacia: Successful treatment by radio-guided tumor surgery

Journal of Clinical Rheumatology

Volumn 15, Issue 1, 2009, Pages 31-34

  Harbeck, Birgit ^a,b   Schöcklmann, Harald ^a   Seekamp, Andreas ^a   Czech, Norbert ^a   Mönig, Heiner ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Hemangiopericytoma; Oncogenic; Osteomalacia

Indexed keywords

CALCITRIOL; CALCIUM; OXIDRONATE TECHNETIUM TC 99M; PENTETREOTIDE IN 111; PHOSPHATE;

ADULT; ANALGESIA; ARTICLE; BONE BIOPSY; BONE PAIN; BONE SCINTISCANNING; CALCIUM INTAKE; CANCER DIAGNOSIS; CANCER SURGERY; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FEMUR NECK; HEMANGIOPERICYTOMA; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS; MALE; METASTASIS; MINERAL INTAKE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENIC OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHOSPHATE URINE LEVEL; PRIORITY JOURNAL; RADIODIAGNOSIS; RIB; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINE; VITAMIN SUPPLEMENTATION;

ADULT; HEMANGIOPERICYTOMA; HUMANS; HYPOPHOSPHATEMIA; INDIUM RADIOISOTOPES; MALE; OSTEOMALACIA;

EID: 67650302482     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181960483     Document Type: Article

References (25)

1. Econs MJ, Drezner MK. Tumor-induced osteomalacia-unveiling a new hormone. N Engl J Med. 1994;330:1679-1681.
2. Kumar R. Phosphatonin-a new phosphaturetic hormone? (Lessons from tumour-induced osteomalacia and X-linked hypophosphataemia.) Nephrol Dial Transplant. 1997;12:11-13.
3. Cai Q, Hodgson S, Kao PC, et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med. 1994;330:1645-1649.
4. Rowe PS, de Zoysa PA, Dong R, et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics. 2000;67:54-68.
5. Berndt T, Craig TA, Bowe AE, et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest. 2003;112:785- 794.
6. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348:1656-1663.
7. White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hy-pophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001;60:2079.
8. Rhee Y, Lee JD, Shin KH, et al. Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin Endocrinol (Oxf). 2001;54:551-554.
9. Jan de Beur SM, Streeten EA, Civelek AC, et al. Localisation of mesenchy-mal tumours by somatostatin receptor imaging. Lancet. 2002;359:761-763.
10. Seufert J, Ebert K, Müller J, et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med. 2001;345:1883-1888.
11. Nguyen BD, Wang EA. Indium-111 pentetreotide scintigraphy of mesenchy-mal tumor with oncogenic osteomalacia. Clin Nucl Med. 1999;24:130-131.
12. Reubi JC, Waser B, Laissue JA, et al. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Res. 1996;56:1922-1931.
13. O'Donnell D, Meyers AM. Hypophosphataemic osteomalacia misdiagnosed as metastatic carcinoma. S Afr Med J. 1985;67:934-935.
14. Clunie GPR, Fox PE, Stamp TCB. Four cases of acquired hypophosphatae-mic ("oncogenic") osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatology. 2000;39:1415-1421.
15. Ros I, Alvarez L, Guanabens N, et al. Hypophosphatemic osteomalacia: a report of five cases and evaluation of bone markers. J Bone Miner Metab. 2005;23:266-269.
16. Dent CE, Friedman M. Hypophosphataemic osteomalacia with complete recovery. Br Med J. 1964;1:1676-1679.
17. Fuentealba C, Pinto D, Ballesteros F, et al. Oncogenic hypophospatemic osteomalacia associated with a nasal hemangioperiytoma. J Clin Rheumatol. 2003;9:373-379.
18. Jan de Beur SM. Tumor-induced osteomalacia. JAMA. 2005;294:1260-1267.
19. Osborn M. Intermediate filaments as histologic markers: an overview. J Invest Dermatol. 1983;81:104s-109s.
20. Schick B, Brors D, Draf W. Experiences with hemangiopericytoma in cranial base surgery. Laryngorhinootologie. 1998;77:256-263.
21. Wilde F, Neid M, Schulz T, et al. Hemangiopericytoma (extrapleural solitary fibrous tumour). Exemplified and discussed on the basis of two cases. Mund Kiefer Gesichtschir. 2005;9:404-408.
22. Hofland LJ, Lamberts SW. Somatostatin receptors and disease: role of receptor subtypes. Baillieres Clin Endocrinol Metab. 1996;10:163-176.
23. Sundaram M, McCarthy EF. Oncogenic osteomalacia. Skeletal Radiol. 2000; 29:117-124.
24. Auethavekiat P, Roberts JF, Biega TJ, et al. Oncogenic osteomalacia associated with hemangiopericytoma localized by octreotide scan. J Clin Oncol. 2005;23:3626-3628.
25. Weber BP, Schrader M, Inniger R. Malignant hemangioperiytomas in the head and neck area. HNO. 1990;38:326-333.